Biogen sets pricing for new MS drug

04/1/2013 | Yahoo

Biogen Idec said it would price its newly approved multiple sclerosis drug Tecfidera at $54,900 annually, lower than those of rivals including Novartis' Gilenya but higher than analysts had forecast. "We think this represents solid value to the MS community and demonstrates our commitment to patient access," Biogen spokeswoman Kate Niazi-Sai said.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health